Colinz Laboratories share news, announcements and annual reports
BSE: 531210Pharmaceuticals & BiotechnologySmall Cap
Share price at the BSE close on 30 Oct 2026. Previous close ₹70.00.
30 Oct: open ₹72.39, high ₹72.39, low ₹67.50
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹17 Cr4,457th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 6.27
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes ₹2.76 crore of one-off items, the largest of them in the quarter to Jun 2026.
- 908.58
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 1.37
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 24.6%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes ₹2.76 crore of one-off items, the largest of them in the quarter to Jun 2026.
- 0.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 1.5%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.04
- Volume, BSEVolume. Shares traded on the last trading day. Volume in the glossary
- 1,008
Colinz Laboratories share news and announcements
438 announcements, routine notices left out, newest first. Page 3 of 9.
Jan 2025
13 Jan · Board meeting
Meeting on 31 Jan 2025: quarterly results8 Jan · Pursuant To Regulation 13 (3) Of The SEBI (Listing Obligations And Disclosure Requirement) Regulations, 2015, The Statement Of Investor Complaints Of The Company For The Quarter Ended 31St December, 2024 Is As Under
8 Jan · Intimation To Exchange Pursuant To Regulation 13(3) Of The SEBI (Listing Obligations And Disclosure Requirement) Regulations, 2015
2 Jan · Declaration With Respect To Non-Applicability Of Related Party Transactions Pursuant To Regulations 23(9) Of The SEBI (Listing Obligations And Disclosure Requirements, Regulation 2015).
Oct 2024
14 Oct · Board meeting
Meeting on 30 Oct 2024: quarterly results5 Oct · Declaration With Respect To Non-Applicability Of Related Party Transactions Pursuant To Regulations 23(9) Of The SEBI (Listing Obligations And Disclosure Requirements, Regulation 2015).
Sep 2024
Aug 2024
1 Aug · Board meeting
Meeting on 8 Aug 2024
Jul 2024
18 Jul · Board meeting
Meeting on 31 Jul 2024: quarterly results4 Jul · Legal
Exchange has sought clarification from Colinz Laboratories Ltd on July 4, 2024 with reference to significant movement in price, in order to ensure that investors have latest relevant ....4 Jul · Declaration With Respect To Non-Applicability Of Related Party Transactions Pursuant To Regulations 23(9) Of The SEBI (Listing Obligations And Disclosure Requirements, Regulation 2015).
May 2024
6 May · Board meeting
Meeting on 29 May 2024: quarterly results
Apr 2024
15 Apr · Compliance Certificate Under Regulation 7(3) Of SEBI(LODR), Regulation, 2015 For The Year Ended 31-03-2024
10 Apr · Compliance Under Regulation 40(9) As On 31-03-24
5 Apr · Declaration Under Regulation 23(9) For Related Party Transactions Non-Applicability As On Mar-2024
Jan 2024
10 Jan · Board meeting
Meeting on 31 Jan 2024: quarterly results5 Jan · PURSUANT TO REGULATION 23(9) OF SEBI(LODR) AND 15(2) NON APPLICABILITY OF RELATED PARTY TRASACTIONS
Nov 2023
7 Nov · DECLARATION WITH RESPECT TO NON-APPLICABILTY OF RELATED PARTY TRASACTIONS PARSUANT TO REGULATION 23(9) OF SEBI(LODR), REGULATION 2015
Oct 2023
16 Oct · Board meeting
Meeting on 31 Oct 2023: quarterly results